Investing Profile

David Grayzel

Photo of David Grayzel, Partner at Atlas Venture

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$500K - $5.0M
$2.0M
8
CompanyStageDateRound SizeTotal Raised
Q32 Bio
Post Ipo EquityMar 2024$42M
Series BOct 2020$60M
Series AMay 2020$46M
$150M
Co-investors: Diyong Xu (OrbiMed), Isaac Manke (Acorn Bioventures)
Comanche Biopharma
Series BJan 2024$75M
$75M
Co-investors: Scott Gottlieb (New Enterprise Associates (NEA))
Triana Biomedicines
Series AApr 2022$110M
$110M
Co-investors: Christopher O'Donnell (Pfizer Venture Investments)
Affinia Therapeutics
Series BMay 2021$110M
Series AMar 2020$60M
$170M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Robert Weisskoff (F-Prime Capital Partners)
Delinia
Series ASep 2016$35M
$35M